Remove Drugs Remove Marketing Remove Medicine Remove Trial Funding
article thumbnail

Trial backs Lilly’s Olumiant plus remdesivir as combo COVID-19 therapy

pharmaphorum

Adding Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir reduces recovery time in COVID-19 patients compared to remdesivir alone, says a new trial. ACTT-2 used a 4mg dose of the drug, which wasn’t approved by the FDA on safety grounds.

Trials 111
article thumbnail

£2 million secured to fuel expansion in early phase clinical trials  

Drug Discovery World

Integrated drug formulation and clinical trials company, BDD Clinical Trials, has secured a further round of investment for £2M to aid the company’s expansion in response to growing demand for both its patented drug delivery technology and specialist clinical trial services.